Page 101 - பல்கலைக்கழகம் ஆஃப் வாஷிங்டன் பள்ளி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sacituzumab Govitecan – Another Antibody Drug Conjugate Carving out a Path in Genitourinary Oncology Published 01 February 2021 I have previously discussed the use of antibody-drug conjugates for selective tumor cell intensification of urothelial carcinoma therapy in a Urotoday Clinical Trials Portal article. 1 Similarly, I’ve also focused on enfortumab vedotin before, and enfortumab vedotin is now FDA approved on the accelerated pathway for patients with locally advanced or metastatic urothelial carcinoma in the post-platinum chemotherapy and post-PD-(L1) antibody therapy setting. 2 Yet, even as new data continues to emerge on the use of enfortumab vedotin in various settings, we should take time to evaluate the development of other promising antibody-drug conjugates.

United statesFred hutchinson cancer research centerUniversity of washingtonJulio hajdenbergArjun vasant balarScottt tagawaAditya bardiaDaniel peterSaby georgePhilip james saylorEvan yuManojkumar bupathiAliciak morgansArash rezazadehRohitk jainBishoy morris faltas